BOLZONI, Marina
 Distribuzione geografica
Continente #
NA - Nord America 2.756
EU - Europa 2.264
AS - Asia 2.077
SA - Sud America 205
AF - Africa 57
Continente sconosciuto - Info sul continente non disponibili 8
Totale 7.367
Nazione #
US - Stati Uniti d'America 2.700
CN - Cina 936
SG - Singapore 617
SE - Svezia 489
IE - Irlanda 433
FI - Finlandia 428
DE - Germania 248
IT - Italia 244
HK - Hong Kong 229
TR - Turchia 193
BR - Brasile 189
NL - Olanda 101
UA - Ucraina 57
CA - Canada 50
FR - Francia 45
CI - Costa d'Avorio 39
AT - Austria 36
RU - Federazione Russa 35
GB - Regno Unito 32
IN - India 32
BE - Belgio 30
RO - Romania 28
CZ - Repubblica Ceca 18
BD - Bangladesh 11
ES - Italia 8
EU - Europa 8
LT - Lituania 8
VN - Vietnam 7
AR - Argentina 6
PL - Polonia 6
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
JP - Giappone 4
KZ - Kazakistan 4
PK - Pakistan 4
ZA - Sudafrica 4
CM - Camerun 3
CO - Colombia 3
IQ - Iraq 3
KH - Cambogia 3
MA - Marocco 3
MX - Messico 3
PH - Filippine 3
TW - Taiwan 3
VE - Venezuela 3
AO - Angola 2
BG - Bulgaria 2
CH - Svizzera 2
DK - Danimarca 2
DZ - Algeria 2
EC - Ecuador 2
HR - Croazia 2
IL - Israele 2
IR - Iran 2
JO - Giordania 2
PT - Portogallo 2
QA - Qatar 2
SM - San Marino 2
AM - Armenia 1
AZ - Azerbaigian 1
BO - Bolivia 1
CG - Congo 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
HU - Ungheria 1
ID - Indonesia 1
JM - Giamaica 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MY - Malesia 1
NG - Nigeria 1
OM - Oman 1
PA - Panama 1
PY - Paraguay 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TN - Tunisia 1
Totale 7.367
Città #
Dublin 432
Chandler 421
Singapore 351
Santa Clara 283
Ashburn 249
Beijing 227
Hong Kong 224
Izmir 165
Dearborn 157
Parma 141
Nanjing 137
Jacksonville 134
Ann Arbor 106
Boardman 97
Princeton 86
Shanghai 84
Munich 76
New York 67
San Mateo 59
Shenyang 59
Kunming 57
Toronto 43
Düsseldorf 42
Nanchang 42
Hebei 41
Abidjan 39
Helsinki 38
Wilmington 37
Columbus 33
Los Angeles 32
Vienna 31
Brussels 30
Jinan 30
Tianjin 29
Jiaxing 28
Moscow 28
Kocaeli 27
Hefei 25
Turku 24
Changsha 23
Marseille 23
Focsani 22
Des Moines 19
Bremen 17
Seattle 17
Brno 15
Milan 15
Norwalk 13
Dallas 11
Hangzhou 11
Council Bluffs 10
Guangzhou 10
Pune 10
Redmond 10
Zhengzhou 10
Chengdu 9
Frankfurt am Main 9
The Dalles 9
Fuzhou 8
London 8
Mestre 8
São Paulo 8
Palermo 7
Philadelphia 7
Taizhou 7
Woodbridge 7
Wuhan 7
Chicago 6
Chongqing 6
Houston 6
Piacenza 6
Madrid 5
Ningbo 5
Porto Alegre 5
Tashkent 5
Torino 5
Warsaw 5
Ahmedabad 4
Belo Horizonte 4
Borås 4
Boston 4
Cambridge 4
Central 4
Dubai 4
Fremont 4
Rockville 4
Rome 4
Salvador 4
San Francisco 4
Stockholm 4
Timisoara 4
Tokyo 4
Amsterdam 3
Brooklyn 3
Contagem 3
Edinburgh 3
Guarulhos 3
Hanoi 3
Jinhua 3
Las Vegas 3
Totale 4.679
Nome #
Are the Myeloma bone microevironment cells tumoral or not? 148
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 138
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 136
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20 136
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 135
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 130
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 126
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 119
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 119
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 119
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 118
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 118
Glutamine dependence and PIK3CA mutations in colon-rectal cancer cells: ATF4 enters the stage 111
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 110
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 110
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 109
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 107
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 106
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 106
The osteoblastic niche in the context of multiple myeloma 105
Bortezomib improves bone integrity in multiple myeloma patients by blocking osteocyte death and autophagy 104
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 101
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 100
Use of traffic crash as a risk assessment scale in hospitalized seniors: A perspective observational study 100
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation 99
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 98
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 98
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 98
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 97
Possible targets to treat myeloma-related osteoclastogenesis 97
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 96
Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells 96
Bone marrow CD14+ cells show different transcriptional profiles in Multiple Myeloma (MM) as compared to smoldering MM and MGUS: overexpression of IL21R and its involvement in osteoclastogenesis 95
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 93
Modulation of non canonical wnt5a/ror2 signaling pathway in human mesenchymal cells increases osteogenic differentiation counterbalancing the effect of myeloma cells 93
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 93
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 93
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 92
Bone marrow monocyte / macrophage derived activin a mediates the osteoclastogenic effects of IL-3 in myeloma 92
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 92
Il mieloma multiplo nell'era dei nuovi farmaci. Patogenesi 90
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 89
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 89
Angiogenesis and multiple myeloma 88
The activation of wnt5a-mediated non canonical wnt signaling in human bone marrow osteoprogenitor cells increases osteoblastogenesis and counterbalances the inhibitory effect of myeloma cells on ror2/fzd5 expression 87
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 87
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 86
Proteasome Inhibitors Block Myeloma-Induced Osteocyte Death in Vitro and in Vivo in Multiple Myeloma Patients 84
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 82
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 82
Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients 81
Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations 81
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 81
The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38 79
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively 79
Relationship between bone imaging features and bone marrow cytokine and chemokine profiles in patients with monoclonal gammopathy 78
Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma 78
Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche 78
Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo 76
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 71
Relationship between presence of osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20 70
Bisphosphonates in multiple myeloma: Preclinical and clinical data. 69
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with Multiple Myeloma bone disease 68
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 68
Relationship between skeletal involvement, cytogenetic features and bone marrow profiles of cytokines and chemokines in patients with monoclonal gammopathy 66
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction 65
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide 65
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 64
Interleukin-3 induces activin A in bone marrow monocytes: role in multiple myeloma patients 63
IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A 63
Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells 62
High ASCT2 activity as a marker of extracellular glutamine dependence in ammoniagenic multiple myeloma cell lines 61
Hypoxia-Inducible Factor (HIF)-1α Is a Therapeutic Target in Myeloma-Induced Angiogenesis 61
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 60
Proteasome inhibitors modulate osteocyte death and autophagy in multiple myeloma 59
Myeloma-Induced osteocyte death was blunted by proteasome inhibitors through the modulation of autophagy 58
The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma 57
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules 56
Ectoenzymes and Their Products As Communicators in the Human Myeloma Niche 54
New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics 53
Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: Impact on myeloma-induced alterations of bone remodeling 50
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+ 49
NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model 49
Assessing satisfaction in simulation among nursing students: psychometric properties of the Satisfaction with Simulation Experience - Italian Version scale 43
Role of osteocytes in myeloma bone disease: Anti-sclerostin antibody as new therapeutic strategy 39
Validity and reliability of the Italian version of painad for postoperative pain assessment in geriatric patients with proximal femur fractures 37
Myeloma and osteoclast relationship 36
Evaluation of a New Automated Mono-Test for the Detection of Aspergillus Galactomannan: Comparison of Aspergillus Galactomannan Ag VirCLIA® Mono-Test with PlateliaTM Aspergillus Ag ELISA Assay 23
Totale 7.547
Categoria #
all - tutte 28.370
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.370


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021358 17 29 13 5 63 9 12 4 112 37 36 21
2021/2022402 7 1 8 42 12 8 36 37 29 40 32 150
2022/20231.687 199 193 124 109 131 183 47 107 519 24 41 10
2023/2024590 24 52 11 15 39 185 50 25 12 37 37 103
2024/20252.053 46 95 109 170 226 227 71 67 263 188 185 406
2025/2026186 186 0 0 0 0 0 0 0 0 0 0 0
Totale 7.547